retatrutide weight loss retatrutide clinical trial status Retatrutide, an experimental weight-loss drug, has not been approved by the The trillion-dollar peptide. Appearing on

A mechanism of action phase 1 study showed that the glycemic efficacy of tirzepatide in T2DM results from concurrent improvements in key components of diabetes pathophysiology, including -cell function, insulin sensitivity, and glucagon secretion (135)

32 It also significantly reduced the secondary composite HF endpoint (cardiovascular death, HF hospitalisation or urgent HF hospital visit), with an RRR of 18%

It's Marketed as "Herbal" or "All-Natural": These products often use misleading language to suggest they work like prescription GLP-1s without containing the actual medication

has acted as a consultant of Boehringer Ingelheim, Dexcom, Eli Lilly, Novo Nordisk and Sanofi and received speaking fees from Eli Lilly, Novo Nordisk and Sanofi